Roche Expands HPV Testing for Cobas 5800 Molecular System
Roche announced the U.S. FDA approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.
Roche announced the U.S. FDA approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.
For women over the age of 65 who have never had a high-risk HPV test, a “catch up” test may improve cervical cancer prevention.
The triage approach offers women and labs a more efficient and effective way to diagnose and manage cervical cancer earlier.
A new study found in a questionnaire that 51.4% of women preferred self-sampling for HPV-based cervical cancer screening.
Read MoreMolecular diagnostics company Seegene today announced the development of a commercialized PCR assay that applies “3 Ct” technology.
Read MoreThe cervical cancer screening tool enables physicians to detect and remove pre-cancerous cells from the cervix during the same appointment.
Read MoreRates of cervical cancer screenings have dropped in the U.S., with rates lowest among Asian and Hispanic women.
Read MoreResults from the IMPACT trial demonstrate clear patient benefit in using Roche’s CINtec PLUS Cytology dual-stain biomarker technology.
Read MoreResearchers have found that many women are screened for cervical cancer too often, while others are not getting tested often enough.
Read MoreResearchers have made new findings, which may improve detection of the human papillomavirus (HPV) in the bloodstream.
Read MoreScientists have created a test to measure antibodies in girls who have received a vaccine for HPV, the leading cause of cervical cancer in women.
Read MoreA recent trend analysis indicates that cervical cancer and mortality rates have remained stable or are dropping, in part, because of screening
Read MoreThe ASCCP Cervical Cancer Screening Task Force has voiced its support for the ACS’s 2020 cervical cancer screening guidelines.
Read MoreWith Pap tests and testing for HPV, cervical cancer rates have significantly declined. However, debate continues about cotesting.
Read MoreThe most commonly reported barriers were screening appointment costs (71%) and follow-up/future treatment costs (44%), according to the study.
Read MoreResearchers developed gold leaf electrodes that, in combination with a CRISPR-based assay, could sensitively detect HPV DNA in human samples.
Read MoreHow p16 and Ki-67 indicate transforming HPV infections.
Read MoreEmerging techniques could help detect the virus leading to cervical cancer in low-income areas and developing nations.
Read More